UBS Just Initiated Coverage of Viking Therapeutics With a Buy Rating and a $94 Target. Here's the Bull Case.
· fool.com · popularity 13/100 · 0 similar stories today · Medicine & Clinical Health (Health & Life Sciences)
Read the original at fool.com →
Summary
Trial results for its weight loss drugs could justify a higher valuation for the clinical-stage biotech. Viking Therapeutics (VKTX +1.56%) received a …
Found in: The Motley Fool. Rating basis: single outlet; outlet tier 2 (unlisted); 1 feeds; feed position 29.